Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Combined medicine for treating HBV infection

A technology of drugs and uses, applied in the field of combined drugs for the treatment of HBV infection, can solve the problems of low conversion rate of serum HBeAg, moderate efficacy of interferon treatment, drug resistance, etc., and achieve the effects of inhibiting HBV infection, reducing the content, and having better effects.

Pending Publication Date: 2020-06-12
CHENGDU MEDICAL COLLEGE
View PDF1 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0003] In order to overcome the problems of low serum HBeAg conversion rate, drug resistance, and interferon treatment efficacy of nucleotide inhibitors, the present invention provides the use of nucleotide inhibitors and statins in the preparation of combined drugs for treating HBV infection

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Combined medicine for treating HBV infection
  • Combined medicine for treating HBV infection

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0016] The specific implementation of the present invention will be further described below in conjunction with the examples, and the present invention is not limited to the scope of the examples.

[0017] The raw materials used in the following examples can be purchased from the market.

[0018] Experiment 1. In vitro study of the combination of lovastatin and lamivudine in HBV-infected cells

[0019] Purpose:

[0020] To evaluate the inhibitory effect of lovastatin and lamivudine drug combination on HBV infection.

[0021] method:

[0022] In HepG2.2.15 cells, lovastatin (10, 25 μM concentration), lamivudine (10, 50 μM concentration), and different drug concentrations of lovastatin and lamivudine were added to HepG2.15 cells, and after 6 days of culture, The supernatant was collected, the expression of HBeAg antigen was detected by ELISA, and the content of HBV DNA was detected by RT-PCR.

[0023] result:

[0024] from figure 1 It can be seen that compared with lamivud...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses an application of a nucleotide inhibitor and statins in preparation of a combined medicine for treating HBV infection. The invention also discloses a combined medicine for treating HBV infection, and belongs to the technical field of medicines. The combined medicine can inhibit HBV infection from multiple aspects of HBV replication, virus assembly and budding, the synergistic effect is achieved, and the effect is better.

Description

technical field [0001] The invention belongs to the technical field of medicines, and in particular relates to a combined medicine for treating HBV infection. Background technique [0002] Hepatitis B virus (HBV) infects about 400 million people and is the most common chronic infectious disease worldwide. It is the main cause of primary hepatocellular carcinoma (HCC), and about 1 million people die from HBV infection every year liver failure, cirrhosis and liver cancer. There are currently two classes of approved drugs for the treatment of chronic HBV infection: nucleotide / nucleoside inhibitors and immunomodulators (such as interferon). Nucleotide / nucleoside inhibitors (such as lamivudine, adefovir dipivoxil, entecavir, etc.) mainly inhibit HBV DNA polymerase, thereby preventing virus replication and leading to a decrease in serum viral DNA. However, the HBsAg seroconversion rate of patients after treatment is low, and side effects such as drug-resistant mutations may occu...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/513A61P31/20
CPCA61K31/366A61K31/22A61K31/513A61K9/0056A61P31/20
Inventor 张涛程琳杨菁
Owner CHENGDU MEDICAL COLLEGE
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com